Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study

Characteristics Total (N = 28)
No. of patients %
Sex Male 13 46.4
Female 15 53.6
Stage at Diagnosis (UICC) I 1 4.2
II 9 37.5
III 3 12.5
IV 11 45.8
Missing 4 -
Stage at Diagnosis (ENSAT) I 1 4.2
II 9 37.5
III 4 16.6
IV 10 41.7
Missing 4 -
Grade Low 1 8.3
High 11 91.7
Missing 16 -
Metastatic disease Yes 19 67.9
No 9 32.1
Sites of Metastasis Local Recurrence 4 14.3
Lymph Node 8 28.6
Lung 10 35.7
Liver 8 28.6
Bone 2 7.1
Other 3 10.7
Functional Tumors at Diagnosis Yes 14 50
No 14 50
PD-L1 Expression on Tumor Cell Membrane <5% (negative) 25 89.3
≥5% (positive) 3 10.7
PD-L1 Expression in Tumor Infiltrating Mononuclear Cells (TIMC)* Score = 0 (negative) 8 29.6
Score > 0 (positive) 19 70.4
  Mean +/− SD Min, Max
Age at Diagnosis (years) 47.4 +/−13.2 19.8 - 73.7
Tumor size (cm) 10.9 +/−4.4 2.5 -19
Mitosis/10HPF 13.7 +/−13.5 0.2-50
  1. *In 1 patient, the PD-L1 staining in TIMC was not assessable.